scholarly journals The F-18 FDG PET/CT evaluation of the metastatic adrenal lesions of the non-lung cancer tumors compared with pathology results

2022 ◽  
Vol 53 (1) ◽  
Author(s):  
Zehra Pınar Koç ◽  
Pınar Pelin Özcan ◽  
Emel Sezer ◽  
Kadir Eser ◽  
Tuba Kara
Keyword(s):  
Lung Cancer ◽  
Adrenal Gland ◽  
Fdg Pet ◽  
Cancer Metastasis ◽  
Unknown Primary ◽  
Adrenal Tumors ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background The aim of this study was to evaluate the role of F-18 FDG PET/CT imaging in the diagnosis of primary and metastatic adrenal tumors that originate from non-lung cancer primary tumors. Results F-18 FDG PET/CT images of patients (8 male and 6 female; mean: 55.36 ± 16.2 years old) who attended with the diagnosis of primary or adrenal metastatic lesions other than lung cancer metastasis were evaluated in a retrospective manner. The diameter of the adrenal lesions was mean: 23.93 ± 36.6 mm with SUVmax levels of mean: 9.98 ± 7.8. The primary site of 2/3 of the patients with unknown primary was the adrenal gland, and in one of the patients primary tumor remained unknown during follow-up. Conclusions According to the results of this study, F-18 FDG PET/CT has high diagnostic performance in the diagnosis of the adrenal gland primary and metastatic lesions, which originate from non-lung cancer tumors. Further studies in the larger series are warranted.

[68Ga]Ga-DOTA-FAPI-04 PET/CT in The Staging of Gastric Cancer: Improved Diagnostic Efficacy Confirmed By Postoperative Histopathology

2021 ◽  
Author(s):  
Rong Lin ◽  
Zefang Lin ◽  
Zhenying Chen ◽  
Shan Zheng ◽  
Jiaying Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Response To Treatment ◽  
Diagnostic Efficacy ◽  
Primary Tumors ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
N Staging

Abstract Purpose This study aimed to compare the diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]-FDG PET/CT in the primary and metastatic lesions of gastric cancer. Methods Fifty-six patients with histologically proven gastric carcinomas were enrolled in this study. Each patient underwent both [18F]-FDG and [68Ga]Ga-FAPI-04 PET/CT within one week. Activity of tracer accumulation in lesions were assessed by maximum standardized uptake value (SUVmax) and TBR (lesions SUVmax/ ascending aorta SUVmean). Histological work-up including immunohistochemical staining for FAP served as a standard of reference. Results [68Ga]Ga-FAPI PET/CT is superior in detecting primary tumors both in patient-based (100% [45/45] vs. 97.8% [44/45]) and lesion-based analyses (97.8% [45/46] vs. 95.7% [44/46]), showing higher SUVmax (10.25 vs. 8.13, P = 0.004) and TBR (11.63 vs. 5.83, P < 0.001), compared with [18F]-FDG PET/CT. The specificity and positive predictive value of [68Ga]Ga-FAPI were significantly higher than that of [18F]-FDG (100.0% vs. 97.7%, P < 0.001; 100.0% vs. 57.1%, P = 0.001) in determining the lymph node (LN) metastases. [68Ga]Ga-FAPI PET/CT was superior to [18F]-FDG PET/CT in N-staging (47.1% [8/17] vs. 23.5% [4/17]), and in evaluation for LN, peritoneum and bone metastases. [68Ga]Ga-FAPI PET/CT detected positive recurrent lesions in all patients and showed more positive lesions and clearer tumor delineation. Two patients underwent follow-up [68Ga]Ga-FAPI PET/CT scans after chemotherapy, which both showed remission. Conclusions [68Ga]Ga-FAPI PET/CT can better detect primary gastric cancer and metastatic lesions in peritoneum, abdominal LNs and bone, showing high usefulness in guiding N staging. Furthermore, [68Ga]Ga-FAPI PET/CT provides more information for patients with recurrence detection and also has great potential in monitoring response to treatment.

scholarly journals Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT

2011 ◽  
Vol 4 (1) ◽  
Author(s):  
Jong Sun Park ◽  
Jae-Joon Yim ◽  
Won Jun Kang ◽  
June-Key Chung ◽  
Chul-Gyu Yoo ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Unknown Primary ◽  
Primary Tumors ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Unknown Primary Tumors

Standardized uptake value differences between primary and metastatic lesions in 18F-FDG PET/CT of patients with lung cancer

2014 ◽  
Vol 56 (11) ◽  
pp. 1329-1335 ◽  
Author(s):  
Nobuyuki Kosaka ◽  
Tatsuro Tsuchida ◽  
Kazunobu Tsuji ◽  
Kazuhiro Shimizu ◽  
Hirohiko Kimura
Keyword(s):  
Lung Cancer ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Value Differences ◽  
Metastatic Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

PET/CT and Occult Primary Tumors

2009 ◽  
Vol 7 (3) ◽  
pp. 239-244 ◽  
Author(s):  
Donald A. Podoloff
Keyword(s):  
Fdg Pet ◽  
Imaging Modalities ◽  
Unknown Primary ◽  
Exact Role ◽  
Primary Tumors ◽  
Patients With Cancer ◽  
The Past ◽  
Pet Ct ◽  
Primary Origin ◽  
Fdg Pet Ct

Within the past 5 years, F-18 fluorodeoxyglucose (FDG) PET/CT has become one of the more frequent imaging modalities in the management of patients with cancer of unknown primary origin. FDG PET/CT detects more sites of metastasis than other modalities, and in 20% to 40% of cases it discloses the site of the primary tumor. Its exact role is yet to be defined because of a lack of prospective clinical trials comparing the performance of PET/CT with conventional anatomic imaging modalities. This article reviews the available literature, attempts to place PET/CT using F-18–labeled FDG in clinical perspective and compares the combined modality with conventional anatomic imaging technologies.

Sign in / Sign up

Export Citation Format

Share Document